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Abstract
Introduction: Langerhans Cell Histiocytosis (LCH) represents a rare benign disorder, previously designated as
“Histiocytosis X”, “Type II Histiocytosis” or “Langerhans Cell Granulomatosis”. Clinical presentation includes osteolysis,
ulcerations of skin and soft tissues but also involvement of the CNS is described.
Because treatment concepts are not well defined the German Cooperative Group on Radiotherapy for Benign
Diseases performed a retrospective analysis.
Methods and material: Eight closely cooperating centres collected patients’ data of the past 45 years. As study
endpoints disease free survival, recurrent disease, death and therapy related side effects were defined.
Results: A total of 80 patients with histologically proven LCH were irradiated within the past 45 years. According to
the LCH classification of Greenberger et al. 37 patients had stage Ia, 21 patients stage Ib, 13 patients stage II and 9
patients stage IIIb and the median age was 29 years. The median Follow up was 54 months (range 9–134 months).
A total of 39 patients had a surgical intervention and 23 patients a chemotherapy regimen.
Radiation treatment was carried out with a median total dose of 15 Gy (range 3–50.4Gy). The median single
fraction was 2 Gy (range 1.8-3 Gy).
Overall, 77% patients achieved a complete remission and 12.5% achieved a partial remission. The long-term control
rate reached 80%. Within an actuarial overall 5-year survival of 90% no radiogenic side and late effects ≥EORTC/RTOG II°
were observed.
Conclusion: In the present study a large collective of irradiated patients was analysed. Radiotherapy (RT) is a very
effective and safe treatment option and even low RT doses show sufficient local control.
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Introduction
Langerhans cell histiocytosis (LCH) is a rare benign his-
tiocytic disorder most commonly characterized by single
or multiple osteolytic bone lesions but also ulcerations
of skin and soft-tissues and also involvement of the CNS
are described.
It is characterized by an uncontrolled clonal prolifera-
tion of Langerhans cells which belong to the normal
human mononuclear-phagocytic system. The pathologic
growth pattern remains still unclear but reactive and
paraneoplastic processes have been discussed [1-4].
Previously designated as “Histiocytosis X”, “Hand-Schuller-
Christian disease”, “Letterer-Siwe-Syndrom”, “Type II Histio-
cytosis” or “Langerhans Cell Granulomatosis” LCH involves
single (single-system disease) or multiple (multiple-system
disease) organ systems [5]. In 60% bony manifestations as
single-system disease with uni- or multifocal lesions but
also multi-system disease with activity in other organ
systems are described [5]. In case of involvement of the
CNS diabetes insipidus is a typical symptom [2]. Patients
with single-system disease tend to do well. Patients with
multiple-system disease sometimes have an unpredictable
outcome but also in patients with only one bony lesion
progression, disseminated disease and fatal outcome is
described [6]. Nevertheless also self-healing and self-limiting
courses are reported.
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of LCH and is effective even at low RT-doses. The first suc-
cessful treatment was described in 1930 by Sosman [7].
Since then, the effectivity of radiotherapy in LCH has been
s h o w ni nal a r g en u m b e ro fp u b l i c a t i o n s[ 4 , 8 - 1 2 ] .
Choosing RT as a treatment option the following
aspects should be respected: the age of patients, the
possibility of radiogenic malignancies, and the semi-benign
character of disease. It is used as a single treatment option
for either bony lesions or other organ involvement but
also in a multimodal approach in combination with
chemotherapy (CTX), surgery or steroids [6,13-16]. The
mechanism of actions induced by ionizing radiation
target cells remains unclear [7,17-21]. Suppression of in-
flammatory processes induced by RT and RT-sensitivity
of Langerhans cells are discussed [8,9,22].
In general, two radiotherapy indications must be dis-
tinguished: The treatment of painful or unstable uni- or
multifocal bone lesions and the treatment of extra-osseous
soft tissue or organ involvement [8].
Because treatment concepts, indication of RT, fraction-
ation and timing of RT are not well defined this retrospect-
ive analysis was performed by the German Coopeartive
Group for Benign Diseases (GCHBD) of the DEGRO.
Methods and material
Eight German closely cooperating radiotherapy centres
collected clinical features, treatment concepts and out-
come data of their patients, treated for LCH during the
past 45 years. Participating institutions were three aca-
demic, four non-academic and one private institution.
To determine the efficacy of RT as study endpoints dis-
ease free survival, recurrent disease, death and therapy
related side effects were defined.
Results
Between 1966 and 2011 a total of 80 patients with histo-
logical proven LCH were irradiated. There were 45 women
and 35 men with a median age of 29 years (range 9–81
years). According to the LCH classification of Greenberger
et al. 37 patients had stage Ia, 21 patients stage Ib, 13
patients stage II and 9 patients stage IIIb (The staging
system proposed by Greenberger et al. [14]). The me-
dian Follow up was 54 months (range 9–134 months). A
total of 39 patients had a surgical intervention and 23
patients a chemotherapy regimen. 24 patients were irra-
diated “up-front” and in 43 patients RT was used as
salvage therapy.
The staging system proposed by Greenberger et al. [14]
Stage I
a) Single monostotic bone lesion
b) Multiple lesions in one or multiple bone
Stage II >24 months of age at diagnosis and having
one or more of the following systems
involved: diabetes insipidus, teeth, gingivae,
lymph nodes, skin, mild lung involvement
(i.e., infiltrates seen on chest radiograph
without pulmonary symptoms or gross
consolidation), focally positive bone marrow
Stage III
a) Age <24 months at diagnosis with any of the
systems involved in stage II
b) Age >24 months with involvement of liver
and/or spleen, massive nodal involvement
(nodes > 5 × 5 cm in several sites above or
below diaphragm), honeycomb lung (major
involvement in all areas with apparent fibrosis),
bone marrow packed
Stage IV Spleen > 6 cm (palpable below costal margin)
and fever >1 month with or without any or
all of the above systems involved
Stage V “Special” monocytosis in peripheral blood > 20%
of differential cell count, in addition to stage
III or IV
Overall 48 patients were treated at more than one site
(range 2–8). Non-bony involvement was treated in 28
patients. The sites were as following: skin (n=8), lymph
nodes (n=7), gingiva (n=5), soft tissue (n=5) and central
nervous system (n=3).For bony involvement the treated
sites were as following (more than one is possible): skull
(n=14), rips (n=12), pelvis (n=8), humerus (n=5), clavicula
(n=6), radius (n=3), ulna (n=3), femur (n=4), spine (n=8),
hand (n=4), foot (n=3) and jaw (n=4).
The median number of follow-up visits was 3.5 times.
Most patients received routiniously radiological examination.
Radiation treatment was carried out with a median total
dose of 15 Gy (range 3–50.4 Gy). The median single frac-
tion was 2 Gy (range 1.8-3 Gy). A total dose of 10 Gy or
less was defined to be a low dose (n=26). Local control
was not significant different in this low dose group com-
pared with group of higher doses. Therefore a real dose
response relationship could not be established.
Patients were treated with 60 Co gamma rays or
5-15MV photons of a linear accelerator (Figure 1).
The RT treatment planning was generally realized simu-
lator based. In the past few years 3D CT-based and if
available MRI based planning was preferred. The target
volume definition included a safety margin ranging from
2 cm depending on the location of the tumor.
Overall, 77% patients achieved a complete remission and
12.5% achieved a partial remission (Figure 2). The long
term control rate reached 80%. The actuarial overall 5 year
survival calculated by Kaplan-Meier Method was 90%.
Radiogenic side and late effects ≥EORTC/RTOG II°
were not observed. No treatment related deaths and no
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a positive documentation was available.
Discussion
This analysis comprises a large collective of patients
treated with radiotherapy for LCH. The following results
emerge from this study:
– RT is a safe and effective treatment option for
patients suffering from LCH.
– Even low RT doses show sufficient local control.
– Side effects are low and no treatment related deaths
were observed.
RT is used since decades in the treatment of LCH
especially bony LCH and is even effective in low RT
doses (Figures 3 and 4a/b/c). Due to the rarity of this
disease treatment concepts are irregular and even the
number of published cases in the literature are low.
All studies reported in literature have a retrospective
nature. Radiotherapy indications should respect the age
of patients, the possibility of radiogenic malignancies,
and the semi-benign character of disease.
In childhood LCH clear treatment recommendations
and guidelines, e.g. by the Euro Histio Net, exist. But
radiotherapy is generally not recommended due to the
long term sequelae. In adult LCH there is a lack of such
recommendations, but they are in preparation.
Therefore we conducted this study, to improve the
knowledge on the effects of radiotherapy.
The largest studies in adult patients come from Klipatrick
[6] and Greenberger [22].
Figure 1 RT Doses.
Figure 2 Results of RT [%] CR: Complete Remission, PR: Partial Remission, NR: No Remission.
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of bony involvement, but also RT for patients with dia-
betes insipidus due to involvement of the skull base is
described in the literature [6,20,21]. In a large analysis
conducted by Klipatrick et al. the data of 263 patients
with biopsy proven LCH were analysed. 40 patients
suffered from diabetes insipidus. The role of RT in the
treatment of diabetes insipidus is discussed controver-
sial because low RT doses did not reverse the need for
vasopressin therapy [6]. Although the authors present a
large collective of patients with LCH, the fact that no
information of RT doses and/or RT techniques are given
must be critically considered. The analysis collected data
from a single institution during 1915 to 1995, so probably
old RT techniques were used that cannot be compared to
today’s status. Greenberger et al. conducted a single centre
study of 127 patients with LCH treated in a multimodal
approach consisting of surgery, RT and chemotherapy.
21 of their patients were irradiated for diabetes insipidus
and four of them reached complete reversal of symp-
toms [22]. A total 98 patients were irradiated because of
bony lesions using RT doses ranging from 100 and 2000
rad. Local control was achieved in 95%.
Because treatment concepts are irregular due to the
rarity of disease and most radiotherapeutic centres have
low experience, Olschewski et al. conducted a patterns
of care study. Only 23 of 123 (18.7%) participating insti-
tutions had experience in the treatment of LCH [21].
Most of the patients were treated because of bony in-
volvement and doses ranged from 2 to 40 Gy. Complete
remission was achieved in 77.5% of cases. These data are
well comparable to our study, but it must be taken into
account that some patients data analysed in the current
study were also included in the patterns of care study.
Another study by Olschewski et al. studied the current
literature. 142 studies were analysed. A Complete remission
Figure 3 Radiation portal of a patient with massive osteolysis
of the skull bone by LCH’.
Figure 4 Pronounced recalcification of the skull bone four
months after radiation treatment with a total dose of 10 Gy
in: a) lateral radiograph b) transversal CT scan (bone window)
c) 3D-CT reconstruction.
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76% in patients with “multi-system disease” was reported
[21]. Also these findings are comparable to the outcome
data of our study.
Another analysis that underlines the effectiveness of
RT in the treatment of LCH is presented by El-Sayed
et al. They showed the data of 17 patients. 15 of them
were irradiated using doses from 30–35 Gy. Two of their
patients suffered from diabetes insipidus and responded
immediately to RT [20]. Most literature data concerning
radiotherapy in adult LCH deal with in uni- or multifocal
osseous single-system disease [16,19]. Summarizing the
results in these bone lesions, the local control rates
ranged from 75-100% and complete remission rates were
up to 85%.
In our analysis data of 80 patients treated with RT
are presented. Most of them (58%) suffered from pain-
ful bony involvement, but also patients with soft tissue
affections, ulceration of the skin and CNS-involvement
were treated. A total of 77% patients achieved a complete
remission and 12.5% achieved a partial remission. The
long term control rate reached 80%. The actuarial overall
5 year survival was 90%. These very good response data
support the findings in the literature. Doses concepts
range from 3 to 50.4 Gy. High doses were given in two
patients that suffered from painful bony involvement of
the femur. These findings can be also compared to the
studies mentioned above [6,20,22].
The dose recommendation for radiotherapy is irregu-
lar and an exact dose-effect relationship has not been
established yet. Doses applied are ranging from 1.4 Gy
up to 45 Gy. In the treatment of adults doses from 10 to
20 Gy are recommended [8].
Total doses should be delivered in fractions of 1–2G y
per day to avoid a possibly limited capacity for tissue
repair mechanisms in larger single doses [8].
Side effects of radiotherapy are extremely rare due to
the limited doses applied and depend on the irradiated
site. Most literature data do not provide any information
about acute side effects of radiotherapy [8] and also in
our analysis no side effects > EORTC/RTOG II° and no
treatment related deaths were observed.
Late side effects of radiotherapy are also rare due to
the low applied dose range [8,19]. The only concern,
that should be considered, is the extremely low dan-
ger of radiation-induced risk of second malignancies.
Greenberger et al. [22] reported a rate of 3.9% for in-
duction of malignant tumors. This analysis has to be
seen critically due to the fact that many children were
treated in this cohort [8,23,24].
Surely, there is some concern about using RT in a
non-malignant disease especially as patients are often
infants. The risk of malignant change in the irradiated
area many years later should be taken seriously. Nowadays
in the megavoltage era the risk is not as high as it was
in the orthovoltage era where many patients whose data
are now published, were treated. In addition also the
risk of the other treatment options especially chemo-
therapy should be considered.
There are several publications that described second
malignancies and induction as e.g. leukemias, teratoma,
malignant menigeomas and osteosarcoms [8,19]. The fact,
that also children were treated should be seen critically
because they have a larger risk of cancer induction and
there is a well-known tendency of patients with LCH to
develop malignancies independent of therapy.
Finally, the radiation treatment techniques have changed
and improved substantially during the last decades. Never-
theless, the indication for radiotherapy for a palliative
treatment in LCH has to be chosen carefully and pos-
sible risks must be taken into account [8].
Conclusion
The present analysis comprises a large collective of pa-
tients treated with histologically proven LCH. Our study
is multicentric in contrast to the most studies were only
single institutional data were published. The outcome
data of our study underline the effectiveness of RT in the
treatment of LCH. RT is a safe and simple treatment
option. Even low RT doses show sufficient local control
and side effects are generally low.
Possible indications for a radiation treatment are:
– Unresectable lesions if a resection would
significantly compromise anatomic function.
– Recurrent or progressive lesions.
– Adjuvant treatment following marginal or
incomplete resection.
– Painful or otherwise symptomatic lesions
compromising quality of life.
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